Тиазолопиримидиниевые системы с кватернизованным атомом азота как перспективные противоопухолевые агенты

Тиазолопиримидиниевые системы с кватернизованным атомом азота привлекают все большее внимание в области разработки новых противоопухолевых препаратов. Их уникальная химическая структура и потенциальные биологические свойства делают их перспективными кандидатами для создания эффективных лекарственных средств. В последние годы исследования показали, что эти соединения обладают значительной активностью против различных типов опухолей, что обусловлено их способностью взаимодействовать с клеточными мишенями, нарушая процессы, критические для выживания и пролиферации опухолевых клеток. Настоящий обзор посвящен анализу текущего состояния исследований в области тиазолопиримидинов, включая синтез, механизмы действия и оценку их противоопухолевого потенциала, с акцентом на важность кватернизованного атома азота в их биологической активности.

1. Miller K. D., Siegel R. L., Lin C. C. et al. Cancer treatment and survivorship statistics, 2016 // CA Cancer J Clin. – 2016. – Vol. 66, № 4. – P. 271–289.

2. Zhong L., Li Y., Xiong L. et al. Small molecules in targeted cancer therapy: advances, challenges, and future perspectives //Signal Transduct Target Ther. – 2021. – Vol. 6, № 1. – P. 201.

3. Pommier Y. Topoisomerase I inhibitors: camptothecins and beyond // Nat Rev Cancer. – 2006. – Vol. 6, № 10. – P. 789–802.

4. Dezhenkova L. G., Tsvetkov V. B., Shtil A. A. Topoisomerase I and II inhibitors: chemical structure, mechanisms of action and role in cancer chemotherapy // Russian Chemical Reviews. – 2014. – Vol. 83, № 1. – P. 82–94.

5. Berman H. M., Young P. R. The interaction of intercalating drugs with nucleic acids // Annu Rev Biophys Bioeng. – 1981. – Vol. 10, № 1. – P. 87–114.

6. Ashley J. N., Browning C. H., Cohen J. B., Gulbransen R. The antiseptic and trypanocidal properties of some anil and styryl derivatives of 4 amino quinaldine // Proceedings of the Royal Society of London. Series B, Containing Papers of a Biological Character. – The Royal Society London, 1933. – Vol. 113, № 783. – P. 293–299.

7. Glen W. L., Sutherland M. M. J., Wilson F. J. et al. The preparation and therapeutic properties of certain 4-substituted quinoline derivatives // Journal of the Chemical Society (Resumed). – Royal Society of Chemistry, 1939. – P. 489–492.

8. Browning C. H., Cohen J. B., Ellingworth S., Gulbransen R. The antiseptic properties of the amino derivatives of styryl and anil quinoline // Proceedings of the Royal Society of London. Series B, Containing Papers of a Biological Character. – The Royal Society London, 1926. – Vol. 100, № 703. – P. 293–325.

9. Hughes B., Bates A. L., Bahner C. T., Lewis M. R. Regression of transplanted rat lymphoma No. 8 following oral administration of either 4-(p-Dimethylaminostyryl) quinoline methiodide or methochloride // Proceedings of the Society for Experimental Biology and Medicine. – SAGE Publications Sage UK: London, England, 1955. – Vol. 88, № 2. – P. 230–232.

10. Bahner C. T., Pace E. S., Prevost R. Quaternary salts of styryl pyridines and quinolines // J Am Chem Soc. – ACS Publications, 1951. – Vol. 73, № 7. – P. 3407–3408.

11. Gutsulyak B. M. Biological Activity of Quinolinium Salts // Russian Chemical Reviews. – 1972. – Vol. 41, № 2. – P. 187–202.

12. Fortuna C. G., Barresi V., Bonaccorso C. et al. Design, synthesis and in vitro antitumour activity of new heteroaryl ethylenes // Eur J Med Chem. – 2012. – Vol. 47. – P. 221–227.

13. Barresi V., Bonaccorso C., Consiglio G. et al. Modeling, design and synthesis of new heteroaryl ethylenes active against the MCF-7 breast cancer cell-line // Mol Biosyst. – The Royal Society of Chemistry, 2013. – Vol. 9, № 10. – P. 2426–2429.

14. Bongiorno D., Musso N., Bonacci P. G. et al. Heteroaryl-ethylenes as new lead compounds in the fight against high priority bacterial strains // Antibiotics. – MDPI, 2021. – Vol. 10, № 9. – P. 1034.

15. Bivona D. A., Mirabile A., Bonomo C. et al. Heteroaryl­ethylenes as new effective agents for high priority gram­positive and gram­negative bacterial clinical isolates // Antibiotics. – 2022. – Vol. 11, № 6. – P. 767.

16. Xie X., Zuffo M., Teulade-Fichou M. P., Granzhan A. Identification of optimal fluorescent probes for G-quadruplex nucleic acids through systematic exploration of mono- And distyryl dye libraries // Beilstein Journal of Organic Chemistry. – Beilstein­Institut Zur Forderung der Chemischen Wissenschaften, 2019. – Vol. 15. – P. 1872–1889.

17. Long W., Zheng B. X., Huang X. H. et al. Molecular recognition and imaging of human telomeric G­Quadruplex DNA in live cells: a systematic advancement of thiazole orange scaffold to enhance binding specificity and inhibition of gene expression // J Med Chem. – J Med Chem, 2021. – Vol. 64, № 4. – P. 2125–2138.

18. Sucunza D., Cuadro A. M., Alvarez-Builla J., Vaquero J. J. Recent advances in the synthesis of azonia aromatic heterocycles // J Org Chem. – 2016. – Vol. 81, № 21. – P. 10126–10135.

19. Krey A. K., Hahn F. E. Berberine: Complex with DNA //Science (1979). – 1969. – Vol. 166, № 3906. – P. 755–757.

20. Bhadra K., Maiti M., Kumar G. S. DNA-binding cytotoxic alkaloids: comparative study of the energetics of binding of berberine, palmatine, and coralyne // DNA Cell Biol. – 2008. – Vol. 27, № 12. – P. 675–685.

21. Bazzicalupi C., Ferraroni M., Bilia A. R. et al. The crystal structure of human telomeric DNA complexed with berberine: an interesting case of stacked ligand to G­tetrad ratio higher than 1:1 // Nucleic Acids Res. – 2013. – Vol. 41, № 1. – P. 632–638.

22. Molina A., Vaquero J. J., Garcia-Navio J. L. et al. Synthesis and DNA binding properties of γ-carbolinium derivatives and benzologues // J Org Chem. – 1996. – Vol. 61, № 16. – P. 5587–5599.

23. Molina A., Vaquero J. J., García-Navio J. L. et al. Azonia derivatives of the γ-carboline system. A new class of DNA intercalators // Bioorg Med Chem Lett. – Pergamon, 1996. – Vol. 6, № 13. – P. 1453–1456.

24. Ihmels H., Faulhaber K., Vedaldi D. et al. Intercalation of organic dye molecules into double-stranded DNA. Part 2: the annelated quinolizinium ion as a structural motif in DNA intercalators // Photochem Photobiol. – Wiley, 2005. – Vol. 81, № 5. – P. 1107–1115.

25. Prasad P., Khan I., Sasmal P. K. et al. Planar triazinium cations from vanadyl-mediated ring cyclizations: the thiazole species for efficient nuclear staining and photocytotoxicity // Dalton Transactions. – The Royal Society of Chemistry, 2013. – Vol. 42, № 13. – P. 4436–4449.

26. Pithan P. M., Decker D., Druzhinin S. I. et al. 8-Styryl-substituted coralyne derivatives as DNA binding fluorescent probes // RSC Adv. – 2017. – Vol. 7, № 18. – P. 10660–10667.

27. Sha X. L., Yang X. Z., Wei X. R. et al. A mitochondria/ lysosome-targeting fluorescence probe based on azonia-cyanine dye and its application in nitroreductase detection //Sens Actuators B Chem. – Elsevier, 2020. – Vol. 307. – P. 127653.

28. Chen Y., Wei X. R., Sun R. et al. The application of azonia-cyanine dyes for nucleic acids imaging in mitochondria //Sens Actuators B Chem. – Elsevier, 2019. – Vol. 281. – P. 499–506.

29. Sha X. L., Niu J. Y., Sun R. et al. Synthesis and optical properties of cyanine dyes with an aromatic azonia skeleton // Organic Chemistry Frontiers. – The Royal Society of Chemistry, 2018. – Vol. 5, № 4. – P. 555–560.

30. Suárez R. M., Bosch P., Sucunza D. et al. Targeting DNA with small molecules: a comparative study of a library of azonia aromatic chromophores // Org Biomol Chem. – 2015. – Vol. 13, № 2. – P. 527–538.

31. Bosch P., García V., Bilen B. S. et al. Imidazopyridinium cations: A new family of azonia aromatic heterocycles with applications as DNA intercalators // Dyes and Pigments. – 2017. – Vol. 138. – P. 135–146.

32. Chuiguk V. A., Rudnik I. A. Mesoionic 1,2,4-triazolo[5′,1′:3,4]-1,2,4-triazolo[1,5-a]-pyrimidines // Chem Heterocycl Compd (N Y). – 1982. – Vol. 18, № 7. – P. 762–762.

33. De Jong W. H., Borm P. J. Drug delivery and nanoparticles: Applications and hazards // Int J Nanomedicine. – 2008. – Vol. 3, № 2. – P. 133.

34. Aslan B., Ozpolat B., Sood A. K., Lopez-Berestein G. Nanotechnology in cancer therapy // J Drug Target. – 2013. – Vol. 21, № 10. – P. 904–913.

35. Roger E., Lagarce F., Garcion E., Benoit J.-P. Biopharmaceutical parameters to consider in order to alter the fate of nanocarriers after oral delivery // Nanomedicine. – 2010. – Vol. 5, № 2. – P. 287–306.

36. Duncan R. Polymer conjugates as anticancer nanomed­ icines // Nat Rev Cancer. – 2006. – Vol. 6, № 9. – P. 688–701.

37. Vega-Villa K. R., Takemoto J. K., Yáñez J. A. et al. Clinical toxicities of nanocarrier systems // Adv Drug Deliv Rev. – 2008. – Vol. 60, № 8. – P. 929–938.

38. Rihova B., Kubackova K. Clinical Implications of N­(2­Hydroxypropyl)Methacrylamide Copolymers // Curr Pharm Biotechnol. – 2003. – Vol. 4, № 5. – P. 311–322.

39. O’Brien M. E. R., Wigler N., Inbar M. et al. Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCl(CAELYXTM/Doxil®) versus conventional doxorubicin forfirst-line treatment of metastatic breast cancer // Annals of Oncology. – 2004. – Vol. 15, № 3. – P. 440–449.

40. Pillai G. Nanomedicines for Cancer Therapy: An Update of FDA approved and those under various stages of development //SOJ Pharm Pharm Sci. – 2014. – Vol. 1, № 2.

41. Stinchcombe T. E. Nanoparticle albumin­bound paclitaxel: a novel cremphor­EL ® ­Free formulation of paclitaxel // Nanomedicine. – 2007. – Vol. 2, № 4. – P. 415–423.

42. Xu R., Fisher M., Juliano R. L. Targeted albumin­based nanoparticles for delivery of amphipathic drugs // Bioconjug Chem. – 2011. – Vol. 22, № 5. – P. 870–878.

43. Ma N., Liu J., He W. et al. Folic acid­grafted bovine serum albumin decorated graphene oxide: An efficient drug carrier for targeted cancer therapy // J Colloid Interface Sci. – Academic Press Inc., 2017. – Vol. 490. – P. 598–607.

44. Wang Y., Wu C. Site-specific conjugation of polymers to proteins // Biomacromolecules. – 2018. – Vol. 19, № 6. – P. 1804–1825.

45. Eisele K., Gropeanu R., Musante A. et al. Tailored Albumin­based copolymers for receptor­mediated delivery of perylenediimide guest molecules // Macromol Rapid Commun. – 2010. – Vol. 31, № 17. – P. 1501–1508.

46. Kopeckova K., Eckschlager T., Sirc J. et al. Nanodrugs used in cancer therapy // Biomedical Papers. – 2019. – Vol. 163, № 2. – P. 122–131.